Compare Recordati SpA with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.96%
0%
-8.96%
6 Months
23.84%
0%
23.84%
1 Year
46.4%
0%
46.4%
2 Years
35.94%
0%
35.94%
3 Years
20.95%
0%
20.95%
4 Years
60.25%
0%
60.25%
5 Years
97.67%
0%
97.67%
Recordati SpA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.56%
EBIT Growth (5y)
2.20%
EBIT to Interest (avg)
16.62
Debt to EBITDA (avg)
1.95
Net Debt to Equity (avg)
1.01
Sales to Capital Employed (avg)
0.58
Tax Ratio
24.13%
Dividend Payout Ratio
62.07%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
19.37%
ROE (avg)
25.39%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
NA
EV to EBIT
18.73
EV to EBITDA
14.53
EV to Capital Employed
NA
EV to Sales
3.78
PEG Ratio
2.65
Dividend Yield
22.89%
ROCE (Latest)
NA
ROE (Latest)
NA
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 3 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
713.40
662.20
7.73%
Operating Profit (PBDIT) excl Other Income
284.20
245.00
16.00%
Interest
24.00
24.90
-3.61%
Exceptional Items
-1.50
-15.00
90.00%
Consolidate Net Profit
153.10
117.30
30.52%
Operating Profit Margin (Excl OI)
324.80%
289.00%
3.58%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 7.73% vs 4.73% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 30.52% vs 6.44% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,618.40
2,341.60
11.82%
Operating Profit (PBDIT) excl Other Income
926.20
826.90
12.01%
Interest
98.90
81.20
21.80%
Exceptional Items
-47.00
-22.40
-109.82%
Consolidate Net Profit
443.60
416.50
6.51%
Operating Profit Margin (Excl OI)
274.90%
281.80%
-0.69%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 11.82% vs 12.45% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 6.51% vs 7.01% in Dec 2024
About Recordati SpA 
Recordati SpA
Pharmaceuticals & Biotechnology
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Company Coordinates 
Company Details
Via M. Civitali, 1 , MILANO None : 20148
Registrar Details






